Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL12 2022 | Using PET-adapted study designs to de-escalate treatment intensity in HL

Peter Borchmann • 25 Oct 2022
ISHL12 2022
Hodgkin Lymphoma Lymphoma ABVD Anthracycline BEACOPP

In this video, Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the value of using PET-adapted study designs to guide treatment and de-escalate treatment intensity in patients with Hodgkin lymphoma (HL), as well as reduce the risk of anthracycline-associated severe delayed side effects. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Borchmann

1:34
PET-guided treatment: the new standard of care in Hodgkin lymphoma?
Peter Borchmann • 15 Jun 2023
1:26
Promising results from the SWOG S1826 trial: nivo-AVD versus BV-AVD in patients with cHL
Peter Borchmann • 15 Jun 2023
2:27
Insights into the BrECADD regimen in HL & results from the GHSG HD21 study
Peter Borchmann • 15 Jun 2023
5:02
HD21: treatment-related morbidity in patients with Hodgkin lymphoma treated with BrECADD vs eBEACOPP
Peter Borchmann • 12 Dec 2022

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals